BMB-101 demonstrated significant anti-seizure benefit in both cohorts with favorable safety and tolerability Absence: 73.1% ...
Date and Time: January 6, 2026, 8AM ET Webcast: ...
Bright Minds Biosciences has debuted glowing phase 2 results for its lead anti-seizure asset, giving the biotech’s stock a ...
Bright Minds Biosciences' BMB-101, a 5-HT2C receptor agonist, shows promise in treating drug-resistant epilepsy, with favorable Phase 1 safety and efficacy data. The company's proprietary platform ...
TipRanks on MSN
Bright Minds Biosciences sets January 6 webcast for BMB-101 phase 2 topline results in drug-resistant absence seizures
Bright Minds Biosciences ( ($TSE:DRUG) ) has issued an update. On January 5, 2026, Bright Minds Biosciences announced plans to report topline ...
Biosciences announced positive and significant topline results from its Phase 2 BREAKTHROUGH clinical trial evaluating ...
- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is highly predictive of sudden unexpected death in epilepsy (SUDEP) - - Findings highlight ...
Bright Minds Biosciences announces Phase 2 Clinical trial to evaluate BMB-101 in a group of drug-resistant epilepsy disorders with high unmet needs BMB-101 is a novel highly selective 5-HT2C agonist.
BTIG initiated coverage on Bright Minds Biosciences Inc. (NASDAQ:DRUG), a clinical-stage company focused on neurological and psychiatric disorders. Investment in Bright Minds is based on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback